https://www.selleckchem.com/pr....oducts/indoximod-nlg
Clonal hematopoiesis driven by somatic mutations in hematopoietic cells, frequently called clonal hematopoiesis of indeterminate potential (CHIP), has been associated with adverse cardiovascular outcomes in population-based studies and in patients with ischemic heart failure (HF) and reduced left ventricular ejection fraction (LVEF). Yet, the impact of CHIP on HF progression, including nonischemic etiology, is unknown. The purpose of this study was to assess the clinical impact of clonal hematopoiesis on HF progression irresp
Curtir
Comentario
Compartilhar
